



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
ROBERTSON et al.)
Serial No. 09/857,739) Art Unit: 1642
Filed: June 8, 2001) Examiner: Misook Yu
For: CANCER DETECTION METHODS AND REAGENTS)


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. The enclosed references were cited by Examiner Canella in co-pending Application No. 09/700,092, filed May 16, 2001. Accordingly, no copies of the references are being furnished. Copies of the cited references will be provided upon the Examiner's request.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,




Jamie L. Greene
Reg. No. 32,467


KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 49409-284704 (0020)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 7, 2006.

ATLLIB02 22985.1



Jamie L. Greene - Reg. No. 32,467



FEB 10 2006

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Approved for use through 10/31/2003 and 08/01/2007
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

WPTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known


Application Number	09/857,739
Filing Date	June 8, 2001
First Named Inventor	Robertson
Group Art Unit	1642
Examiner Name	Yu
Attorney Docket Number	02332-0020 (49409-284704)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.



Substitute Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/857,739
Filing Date	June 8, 2001
First Named Inventor	Robertson
Group Art Unit	1642
Examiner Name	Yu
Attorney Docket Number	02332-0020 (49409-284704)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-	7	Petrarca, C., "Human Antibodies Against the Polymorphic Epithelial Mucin in Ovarian Cancer Patients Recognise a Novel Sequence in the Tandem Repeat Region"; <i>European Journal of Cancer</i> , Vol. 32A, No. 12, pp. 2155-2163, 1996	
-	8	Von Mensdorff-Pouilly, S., "Humoral Immune Response to Polymorphic Epithelial Mucin (MUC-1) inpatients with Benign and Malignant Breast Tumours"; <i>European Journal of Cancer</i> , Vol. 32A, No. 8, pp. 1325-1331, 1996	
-	9	Gourevitch, MM; "Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients"; <i>British Journal of Cancer</i> , 72, pp. 934-938; (1995)	
-	10	Sahin et al.; PNAS, 1995, Vol. 92, pp. 11810-11813	
-	11	Scanlan et al.; <i>International Journal of Cancer</i> , 1998, Vol. 76, pp. 652-658	
-	12	Petrakou et al.; <i>International Journal of oncology</i> , 1997, Vol. 11, suppl. Page 902	
-	13	Koterra et al.; <i>Cancer Research</i> , 1994, Vol. 54, pp. 2856-2860	
-	14	Abstract of Mensdorf-Pouilly et al.; <i>Anticancer Research</i> , Nov-Dec. 1997, Vol. 17, page 4184	
-	15	Denton et al.; <i>Cancer Letters</i> , 1993, Vol. 70, pp. 143-150	
-	16	Zisman et al.; <i>Journal of Urology</i> , 1995, Vol. 154, pp. 1052-1055	
-	17	Deguchi et al.; <i>Int. Arch. Allergy Appl. Immunol.</i> , 1988, Vol. 87, pp. 313-316	
-	18	Abstract of Yamamoto et al.; <i>Proc. Amer. Soc. Cancer Res.</i> , March 1997, page 564	
-	19	Disis et al.; <i>Journal of Clinical Oncology</i> , 1997, Vol. 15, pp. 3363-3367	
-	20	Croce et al.; <i>Cancer. Immunol. Immunother.</i> , 1995, Vol. 40, pp. 132-137	
-	21	Green et al.; <i>European Journal of Cancer</i> , 1994, Vol. 30A, pp. 580-584	
-	22	Stearns et al.; <i>Breast Cancer Research and Treatment</i> , 8 Feb. 1998, Vol. 52, pp. 239-259	
-	23	Kawahara; <i>Cancer</i> , 1986, Vol. 58, pp. 2008-2012	
-	24	Abstract of Hayes; <i>Anticancer Drugs</i> , 1995, Vol. 6, suppl. 2, pp. 26-27	
-	25	Abstract of Pandha et al.; <i>Cancer Gene Therapy</i> , 1997, Vol. 4, No. 5, page 310	
-	26	Bhatti et al.; <i>Journal of Tumor Marker Oncology</i> , Summer-1994, Vol. 9, pp. 125-131	
-			
-			
-			
-			
-			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.